Argatroban

Authors: McKeage K.; Plosker G.L.

Source: Drugs, Volume 61, Number 4, 2001 , pp. 515-522(8)

Buy & download fulltext article:

Price: $68.55 plus tax (Refund Policy)

Abstract:

utrif Argatroban is a direct thrombin inhibitor synthesised to bind to the catalytic site of the thrombin molecule. It binds rapidly and reversibly to both clot-bound and soluble thrombin.

utrif The relatively short elimination half-life of argatroban (39 to 51 minutes) and its reversible binding allow rapid achievement of therapeutic effect on initiation of therapy and rapid restoration of normal haemostasis upon cessation of therapy.

utrif Argatroban produces a predictable dose response that is well correlated with changes in anticoagulant parameters.

utrif Argatroban, given to patients with heparin-induced thrombocytopenia (HIT) and heparin-induced thrombocytopenia with thrombosis (HITTS) in a large scale, nonrandomised, prospective trial, reduced a combined end-point of morbidity and mortality when compared with historical controls.

utrif Argatroban was well tolerated in clinical trials of patients with HIT and caused no increase in bleeding risk compared with historical controls.

Keywords: Argatroban, general; New drug profiles; Thrombin inhibitors, general; Thrombosis, treatment

Language: English

Document Type: New drug profile

Affiliations: 1: Adis International Limited, Auckland, New Zealand *

Publication date: 2001-01-01